Eli Lilly and Company · NYSE (us_market)
Healthcare · Drug Manufacturers - General · United States
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-07$1,108.09 RISE2026-04-29$851.21 PEAK2026-05-28$1,126.80 141d | -23.2% 112d | Missed | Missed | — | — | +32.4% 29d | Missed |
DROP2025-04-30$898.95 RISE2025-08-08$625.65 PEAK2025-11-03$896.53 187d | -30.4% 100d | Missed | Missed | — | — | +43.3% 87d | Missed |
DROP2025-03-05$929.72 RISE2025-04-10$720.91 PEAK2025-04-30$898.95 56d | -22.5% 36d | Missed | Missed | — | — | +24.7% 20d | Missed |
DROP2024-09-12$935.02 RISE2025-01-17$725.72 PEAK2025-03-03$929.72 172d | -22.4% 127d | Missed | Missed | — | — | +28.1% 45d | Missed |
DROP2024-08-30$960.02 RISE2024-11-18$727.20 PEAK2025-02-07$878.31 161d | -24.3% 80d | Missed | Missed | — | — | +20.8% 81d | Missed |
DROP2024-07-15$950.46 RISE2024-08-07$772.14 PEAK2024-08-30$960.02 46d | -18.8% 23d | Missed | Missed | — | — | +24.3% 23d | Missed |
DROP2022-12-02$374.76 RISE2023-03-07$310.63 PEAK2023-05-19$442.38 168d | -17.1% 95d | Missed | Missed | — | — | +42.4% 73d | Missed |
DROP2021-12-16$279.04 RISE2022-02-14$234.69 PEAK2022-04-08$311.69 113d | -15.9% 60d | Missed | Missed | — | — | +32.8% 53d | Missed |
DROP2021-08-17$272.71 RISE2021-09-28$221.60 PEAK2021-12-16$279.04 121d | -18.7% 42d | Missed | Missed | — | — | +25.9% 79d | Missed |
DROP2021-01-26$212.72 RISE2021-04-28$180.55 PEAK2021-07-23$244.15 178d | -15.1% 92d | Missed | Missed | — | — | +35.2% 86d | Missed |
DROP2021-01-26$212.72 RISE2021-03-24$180.17 PEAK2021-06-10$233.54 135d | -15.3% 57d | Missed | Missed | — | — | +29.6% 78d | Missed |
DROP2020-07-08$169.13 RISE2020-10-30$130.46 PEAK2021-01-26$212.72 202d | -22.9% 114d | Missed | Missed | — | — | +63.1% 88d | Missed |
DROP2020-02-05$147.35 RISE2020-03-23$119.05 PEAK2020-06-16$163.71 132d | -19.2% 47d | Missed | Missed | — | — | +37.5% 85d | Missed |
Lilly has split its stock in the past.
United States Supreme Court upholds a $220 million Medicaid fraud verdict against Eli Lilly under the False Claims Act. Decision stems from a whistleblower case and concludes a 12 year legal dispute. Ruling is described as the first jury verdict against a pharmaceutical company under this statute. Eli Lilly, NYSE: LLY, now has a material legal setback sitting alongside a large market valuation, with the stock recently trading around $1,126.80. The company has very large multi year share...
The stock market hit fresh highs on Iran deal hopes. Nvidia, Tesla lead five trillion-dollar titans near buy points.
We just covered the Claude Stock Portfolio: Top 10 Stocks to Buy According to AI Chatbot. Eli Lilly and Company (NYSE:LLY) ranks #2 (see Claude Stock Portfolio: Top 5 Stocks to Buy According to AI Chatbot). Number of Hedge Funds: 137 Eli Lilly and Company (NYSE:LLY) is among the top stock picks of the Claude […]
Eli Lilly is near an all-time high in Friday's stock market after a strong first-quarter report. Shares are below a 1133.95 pivot.
Eli Lilly hits a record high after CVS expands coverage for Foundayo and Zepbound, boosting obesity drug access and raising the stakes in its rivalry with NVO.
CVS restores broader Zepbound coverage after price cuts, putting Wegovy and Zepbound on equal footing.
LLY's $4B vaccine push is boosting interest in healthcare ETFs like IHE with heavy exposure to the drugmaker.
Wall Street closed higher on Thursday, driven by tech and healthcare stocks.
Eli Lilly and Company (NYSE:LLY) was among the stocks Jim Cramer discussed on Mad Money, highlighting several companies with market caps over a trillion dollars. Cramer highlighted the company’s new cholesterol drug’s Phase 3 trial, as he commented: Finally, the 11th largest US company, holy cow…. smaller than Micron but still just over 1 trillion, […]
Eli Lilly and Company (NYSE:LLY) is one of the 12 Most Profitable Stocks to Invest In. On May 25, 2026, Eli Lilly and Company (NYSE:LLY) announced positive Phase 1b Heart-2 study results for Verve-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood […]
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the afternoon session after CVS restored Zepbound as a co-preferred option and simultaneously added Lilly's new oral obesity pill Foundayo, making Eli Lilly's full obesity medication portfolio accessible to all three of America's largest pharmacy benefit managers for the first time.
The change could improve patient access and support future sales growth.
The move gives patients broader access to Lilly's obesity drugs and strengthens competition with Novo Nordisk.
Lilly will continue global launches despite MFN pricing uncertainty, Japan price cuts, and rising obesity-drug competition.
U.S. and Iranian negotiators agreed on a 60-day memorandum of understanding to extend the ceasefire, media reports suggested.
Megacap stocks dominate their sectors and their actions influence economies worldwide. The flip side though is that their sheer size means they have less room for explosive growth as scale works against them.
Eli Lilly and Company (NYSE:LLY) is included among the 10 Best Reddit Stocks to Buy According to Billionaires. On May 26, Reuters reported that Eli Lilly and Company (NYSE:LLY) plans to acquire three vaccine developers in deals worth up to $3.8 billion combined, marking a deeper push into infectious disease prevention. The US drugmaker said […]
The stock market rode a big rally in software stocks to fresh highs on Thursday despite another hot inflation report. The Nasdaq gained 0.9%. The Dow rose 25 points to post a slight gain and eke out a fresh record, too.
Eli Lilly shares are on pace to hit a new all-time closing high on news of increased insurance coverage for its blockbuster weight-loss drug Zepbound. Lilly shares were recently up 4.4% to $1,130.90. Pharmacy-benefit manager CVS Caremark decided to add back Lilly’s Zepbound weight-loss drug to its lists of preferred drugs.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| LLY | +14.71% | +8.55% | +2.82% | +49.80% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +11.74% | +14.26% | +6.26% | +37.11% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 35.61M | $32.75B | 1.13% | Added+0.7% | 2026-03-31 |
| FidelityFMR | fundamental | 26.34M | $24.23B | 1.28% | Added+2.4% | 2026-03-31 |
| CapResearch | fundamental | 24.63M | $22.65B | 3.51% | Unchanged | 2026-03-31 |
| Wellington | fundamental | 13.43M | $12.35B | 2.31% | Added+0.5% | 2026-03-31 |
| DEShaw | quant | 637.4K | $586.24M | 0.35% | Added+52.1% | 2026-03-31 |
| Citadel | multi-strat | 95.8K | $88.08M | 0.11% | Added+41.4% | 2026-03-31 |
| RenTech | quant | 71.8K | $66.03M | 0.10% | Trimmed-56.7% | 2026-03-31 |
| Bridgewater | macro | 70.8K | $65.13M | 0.29% | Trimmed-3.4% | 2026-03-31 |
| TwoSigma | quant | 64.5K | $59.37M | 0.05% | Added+394.0% | 2026-03-31 |
| Soros | macro | 22.2K | $20.42M | 0.22% | Trimmed-0.6% | 2026-03-31 |
| TRowePrice | fundamental | 13.99M | $12.87M | 1.49% | Trimmed-6.2% | 2026-03-31 |
| ARKK | disruptive | 12.7K | $11.66M | 0.09% | New | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-19 | Alvarez Ralph | Director | A Grant / award | 13 | $988.09 | +$12.4K |
| 2026-05-19 | Fyrwald J Erik | Director | A Grant / award | 10 | $988.09 | +$9.9K |
| 2026-05-19 | LUCIANO JUAN R | Director | A Grant / award | 16 | $988.09 | +$15.9K |
| 2026-05-19 | Sulzberger Gabrielle | Director | A Grant / award | 5 | $988.09 | +$5.0K |
| 2026-05-07 | LILLY ENDOWMENT INC | Former 10% Shareholder | S Open-market sale | 2,208 | $996.18 | −$2.20M |
| 2026-05-07 | LILLY ENDOWMENT INC | Former 10% Shareholder | S Open-market sale | 13,620 | $995.23 | −$13.55M |
| 2026-04-21 | Alvarez Ralph | Director | A Grant / award | 13 | $919.90 | +$12.4K |
| 2026-04-21 | Fyrwald J Erik | Director | A Grant / award | 11 | $919.90 | +$9.9K |
| 2026-04-21 | LUCIANO JUAN R | Director | A Grant / award | 17 | $919.90 | +$15.9K |
| 2026-04-21 | Sulzberger Gabrielle | Director | A Grant / award | 5 | $919.90 | +$5.0K |
| 2026-03-17 | Alvarez Ralph | Director | A Grant / award | 13 | $989.12 | +$12.4K |
| 2026-03-17 | Fyrwald J Erik | Director | A Grant / award | 10 | $989.12 | +$9.9K |
| 2026-03-17 | LUCIANO JUAN R | Director | A Grant / award | 16 | $989.12 | +$15.9K |
| 2026-03-17 | Sulzberger Gabrielle | Director | A Grant / award | 5 | $989.12 | +$5.0K |
| 2026-02-19 | Dozier Eric | EVP, Chief People Officer | G Gift | 481 | — | +$0 |
| 2026-02-18 | Brown Adrienne S | EVP, President LLY Imm | M Option exercise(deriv) | 391 | — | +$0 |
| 2026-02-18 | Brown Adrienne S | EVP, President LLY Imm | F Tax withholding | 170 | $1040.00 | −$176.8K |
| 2026-02-18 | Brown Adrienne S | EVP, President LLY Imm | M Option exercise | 391 | — | +$0 |
| 2026-02-18 | Custer Kenneth L. | EVP & President, Card Met Hlth | M Option exercise(deriv) | 207 | — | +$0 |
| 2026-02-18 | Custer Kenneth L. | EVP & President, Card Met Hlth | F Tax withholding | 91 | $1040.00 | −$95.0K |
| 2026-02-18 | Custer Kenneth L. | EVP & President, Card Met Hlth | M Option exercise | 207 | — | +$0 |
| 2026-02-18 | Montarce Lucas | EVP & CFO | M Option exercise(deriv) | 368 | — | +$0 |
| 2026-02-18 | Montarce Lucas | EVP & CFO | F Tax withholding | 160 | $1040.00 | −$166.1K |
| 2026-02-18 | Montarce Lucas | EVP & CFO | M Option exercise | 368 | — | +$0 |
| 2026-02-18 | Zakrowski Donald A | SVP, Finance, & CAO | M Option exercise(deriv) | 184 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | 8.81 | — | — |
| 2026-04-30 | 6.79 | 8.55 | +25.90% |
| 2026-02-04 | 6.91 | 7.54 | +9.14% |
| 2025-10-30 | 5.89 | 7.02 | +19.15% |
| 2025-08-07 | 5.59 | 6.31 | +12.89% |
| 2025-05-01 | 3.46 | 3.34 | -3.39% |
| 2025-02-06 | 5.07 | 5.32 | +5.00% |
| 2024-10-30 | 1.47 | 1.18 | -19.52% |
| 2024-08-08 | 2.77 | 3.92 | +41.68% |
| 2024-04-30 | 2.49 | 2.58 | +3.67% |
| 2024-02-06 | 2.37 | 2.49 | +5.14% |
| 2023-11-02 | -0.12 | 0.10 | +181.53% |
| 2023-08-08 | 1.99 | 2.11 | +5.92% |
| 2023-04-27 | 1.73 | 1.62 | -6.33% |
| 2023-02-02 | 1.83 | 2.09 | +14.11% |
| 2022-11-01 | 1.94 | 1.98 | +2.07% |